Aptose Biosciences Inc (APTO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Aptose Biosciences Inc (APTO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10040
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:59
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:カナダ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company which focuses on diagnostics, therapies and treatment for patients with life-threatening cancers. The company advances in new therapeutics which focuses on cellular targets of cancer research coupled with companion diagnostics to identify patient with cancer. Its small molecule cancer therapeutics pipeline includes products which are designed to provide single agent efficacy and efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The company’s product portfolio comprises of CG’806, is a non-covalent small molecule therapeutic agent. Aptose is headquartered in Toronto, Ontario, Canada.

Aptose Biosciences Inc (APTO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deal Details 11
Private Equity 11
Aptose Biosciences to Raise up to USD20 Million in Financing 11
Partnerships 13
Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13
Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15
Licensing Agreements 17
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17
OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19
Equity Offering 20
Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20
Aptose Biosciences Raises Funds through Public Offering of Shares 21
Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$25.3 Million 22
Lorus Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$7.7 Million 24
Lorus Therapeutics Completes Private Placement Of Units For US$0.9 Million 26
Lorus Therapeutics Completes Private Placement Of Units For US$6.6 Million 27
Aptose Biosciences Inc – Key Competitors 29
Aptose Biosciences Inc – Key Employees 30
Aptose Biosciences Inc – Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 32
Financial Announcements 32
Nov 06, 2018: Aptose reports results for the third quarter ended september 30, 2018 32
Aug 07, 2018: Aptose reports results for the second quarter ended june 30, 2018 35
May 10, 2018: Aptose Reports Results for the First Quarter Ended March 31, 2018 37
Mar 27, 2018: Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017 39
Nov 14, 2017: Aptose Reports Results for the Third Quarter Ended September 30, 2017 41
Aug 08, 2017: Aptose Reports Results for the Second Quarter Ended June 30, 2017 43
May 11, 2017: Aptose Reports Results for the First Quarter Ended March 31, 2017 45
Mar 28, 2017: Aptose Reports Fourth Quarter and Year End 2016 Results 47
Corporate Communications 51
Aug 15, 2018: Aptose Biosciences appoints Carol Ashe as Board Director 51
Apr 25, 2018: Aptose Names Caroline M. Loewy As Board Director 52
Mar 27, 2017: Aptose Announces Planned Departure of Chief Business Officer 53
Legal and Regulatory 54
Feb 07, 2018: Aptose Biosciences Files New Preliminary Base Shelf Prospectus to Replace Expired Base Prospectus 54
Product Approvals 55
Jun 29, 2018: FDA Lifts Clinical Hold so MYC Inhibitor APTO-253 Can Return to Phase 1b Trial In Patients With Hematologic Cancers 55
Clinical Trials 56
Jun 04, 2018: Aptose Announces Two Publications of Preclinical Data Elucidating the Anticancer Mechanism of Action of APTO-253 56
Apr 17, 2018: Aptose Presents Preclinical Data on APTO-253 at 2018 AACR Annual Meeting 57
Mar 15, 2018: Aptose to Present Preclinical Data of APTO-253 at the 2018 AACR Annual Meeting 58
Appendix 59
Methodology 59
About GlobalData 59
Contact Us 59
Disclaimer 59

List of Tables
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Aptose Biosciences to Raise up to USD20 Million in Financing 11
Aptose Biosciences Enters into Agreement with Laxai Avanti Life Sciences 13
Lorus Therapeutics Enters Into Agreement With Brock University To Develop Novel Anticancer Drugs 14
Cancer Research UK Enters Into Co-Development Agreement With Lorus To Develop Cancer Drug 15
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 17
OHM Oncology Enters into Licensing Agreement with Aptose Biosciences 18
Aptose Biosciences Enters into Licensing Agreement with CrystalGenomics 19
Aptose Biosciences Files Shelf Prospectus to Raise up to USD100 Million in Public Offering of Shares 20
Aptose Biosciences Raises Funds through Public Offering of Shares 21
Lorus Therapeutics Completes Underwriters Exercise Of Over-Allotment Option Of Public Offering Of Shares For US$25.3 Million 22
Lorus Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For Public Offering Of Shares For US$7.7 Million 24
Lorus Therapeutics Completes Private Placement Of Units For US$0.9 Million 26
Lorus Therapeutics Completes Private Placement Of Units For US$6.6 Million 27
Aptose Biosciences Inc, Key Competitors 29
Aptose Biosciences Inc, Key Employees 30
Aptose Biosciences Inc, Other Locations 31

List of Figures
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Aptose Biosciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Aptose Biosciences Inc (APTO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Samyang Comtech Co., Ltd.:企業の戦略・SWOT・財務情報
    Samyang Comtech Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samyang Comtech Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • New Britain Palm Oil Limited:企業の戦略・SWOT・財務情報
    New Britain Palm Oil Limited - Strategy, SWOT and Corporate Finance Report Summary New Britain Palm Oil Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Prothena Corp Plc (PRTA)-医療機器分野:企業M&A・提携分析
    Summary Prothena Corp Plc (Prothena) is a biotechnology company that discovers, develops and markets novel antibodies that are indicated for the treatment of diseases associated with amyloid or cell adhesion. The company develops monoclonal antibodies directed specifically at disease-causing protein …
  • Allscripts Healthcare Solutions Inc (MDRX):企業の財務・戦略的SWOT分析
    Allscripts Healthcare Solutions Inc (MDRX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Energy Recovery Inc (ERII):企業の財務・戦略的SWOT分析
    Energy Recovery Inc (ERII) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • E.Sun Financial Holding Co Ltd:企業の戦略・SWOT・財務情報
    E.Sun Financial Holding Co Ltd - Strategy, SWOT and Corporate Finance Report Summary E.Sun Financial Holding Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Henry Schein, Inc.:企業の戦略・SWOT・財務情報
    Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report Summary Henry Schein, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Grindeks (GRD1R):製薬・医療:M&Aディール及び事業提携情報
    Summary Grindeks focuses on the research, development, manufacture and marketing of novel pharmaceuticals, generic products and active pharmaceutical ingredients (APIs). Its products are indicated for treating diseases in cardiovascular, central nervous system (CNS) and cancer therapeutic categories …
  • Adaptive Biotechnologies Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Adaptive Biotechnologies Corp (Adaptive) specializes in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. The company’s product portfolio comprises immunoSEQ and clonoSEQ. It provides immunosequencing platform to laboratories for conductin …
  • Auven Therapeutics Management LLLP-製薬・医療分野:企業M&A・提携分析
    Summary Auven Therapeutics Management LLLP (Auven Therapeutics Management), formerly Celtic Therapeutics Management LLLP is a private equity firm that provides life science investment strategy. The firm invests in therapeutic products or platforms. It has invested in diversified portfolio of biologi …
  • Cafe De Coral Holdings Limited:企業の戦略・SWOT・財務分析
    Cafe De Coral Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Cafe De Coral Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • HeidelbergCement AG:戦略・SWOT・企業財務分析
    HeidelbergCement AG - Strategy, SWOT and Corporate Finance Report Summary HeidelbergCement AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Montefiore Medical Center-製薬・医療分野:企業M&A・提携分析
    Summary Montefiore Medical Center (MMC) is a healthcare service provider that offers clinical services. The center offers services such as allergy and immunology, orthopaedics, dentistry and oral surgery, dermatology, endocrinology, digestive and liver diseases, neurological surgery, otorhinolaryngo …
  • The Islamic Insurance Company:企業の戦略・SWOT・財務情報
    The Islamic Insurance Company - Strategy, SWOT and Corporate Finance Report Summary The Islamic Insurance Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Gradalis Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Gradalis Inc (Gradalis), formerly Murex Pharmaceuticals Inc, is a biopharmaceutical company that provides development and commercialization of therapies for the treatment of cancer. The company’s developmental pipeline comprises of candidates for various cancer indications which include ovar …
  • Presidio Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Presidio Pharmaceuticals Inc (Presidio) is a clinical-stage pharmaceutical company that discovers and develops small-molecule antiviral therapeutics. The company’s products include HCV NS5A, NS5B proteins, lead pan-genotypic HCV NS5A inhibitor, ravidasvir hydrochloride, protease inhibitor, f …
  • Traverse Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Traverse Biosciences Inc (Traverse Biosciences) is an privately held bioscience company that commercializes drug candidates for the treatment of inflammatory diseases and age-related conditions affecting humans and companion animals. The company provides lead candidate TRB-N0224 which is dev …
  • PacifiCorp:発電所・企業SWOT分析
    PacifiCorp - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executi …
  • eLong, Inc.:企業の戦略・SWOT・財務情報
    eLong, Inc. - Strategy, SWOT and Corporate Finance Report Summary eLong, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Australian Gas Networks Ltd-エネルギー分野:企業M&A・提携分析
    Summary Australian Gas Networks Ltd (Australian Gas Networks) formerly Envestra Ltd, is an oil and gas company that distributes and transports natural gas. The company offers services such as managing the haulage of gas through each network, operation and maintenance of gas network, design an constr …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆